Apixaban, marketed as Eliquis, is expected to see generic availability in 2026, although this timeline is subject to ongoing patent challenges and litigation.
When will the first generic apixaban be available?
The first generic versions of apixaban are anticipated to become available in the United States around May 2026, based on patent expiry dates [1]. However, this date is not definitive due to legal disputes [2].
What are the main patents protecting Eliquis?
Eliquis is protected by several patents. The most significant ones often cited in legal challenges relate to its composition of matter and methods of use [3]. Key patents that are central to the current landscape include U.S. Patent Nos. 8,440,701 and 8,603,999, among others [2].
Why are companies challenging apixaban patents?
Multiple generic drug manufacturers have filed Abbreviated New Drug Applications (ANDAs) and are challenging the validity of Eliquis patents. These challenges aim to invalidate or circumvent the existing patents, thereby clearing the way for earlier generic market entry [4]. Bristol Myers Squibb and Pfizer, the manufacturers of Eliquis, are actively defending these patents [2][4].
What is the legal status of apixaban patents?
The patent landscape for apixaban is complex and contested. While some patents are set to expire in 2026, litigation is ongoing. Patent challenges have led to varied outcomes in different court districts, creating uncertainty regarding the exact timing of generic entry [2][4]. Information on the status of these patents can be found on DrugPatentWatch.com [1].
How does apixaban work?
Apixaban is an anticoagulant that functions as a direct factor Xa inhibitor. By inhibiting factor Xa, it reduces thrombin generation, which is a key component in the blood clotting process [1]. This mechanism helps prevent blood clots from forming and growing.
What are the uses of apixaban?
Apixaban is prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE [1].
What are the risks or side effects of apixaban?
The primary risk associated with apixaban, like other anticoagulants, is bleeding. Patients may experience minor bleeding such as bruising or nosebleeds, but serious or life-threatening bleeding can also occur [1].
What are alternative anticoagulants to apixaban?
Other anticoagulant medications include warfarin, rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa) [5]. These drugs differ in their mechanisms of action, dosing regimens, monitoring requirements, and side effect profiles [5].
Who are the manufacturers of apixaban and its potential generics?
The originator of apixaban is Bristol Myers Squibb and Pfizer [1]. Several generic pharmaceutical companies, such as Viatris, Accord Healthcare, and others, are involved in the development and potential launch of generic apixaban [4].
What is the projected market impact of generic apixaban?
The introduction of generic apixaban is expected to significantly reduce the cost of this medication. This could lead to increased patient access and a substantial shift in market share from the branded product to generic alternatives [1][4].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/drug/apixaban/patent-litigation
[3] https://www.drugpatentwatch.com/drug/apixaban/patents
[4] https://www.drugpatentwatch.com/drug/apixaban/generics
[5] https://www.drugpatentwatch.com/drug/rivaroxaban/alternatives